JAK2 and essential thrombocythemia: However, PV and ET patients who presented an additional non-driver mutation, such as TP53, ASXL1, RUNX1, SRSF2 and IDH2/2, have persistent increase in JAK2 V617F allele burden while receiving HU treatment.